natgillin/translations-raw huggingface dataset:
Viscoelastic gels and hydrogels for use according to any one of claims 1-3, wherein the hyaluronic acid used for the preparation of ACP and HBC derivatives is preferably a hyaluronic acid sodium salt and has a weight-average molecular weight from 400 to 3x106Da, preferably from 1x 105Da to 1x 106Da, most preferably from 200,000 to 750,000 Da. 
Viskoelastični gelovi i hidrogelovi za primjenu prema bilo kojem od patentnih zahtjeva 1-3, naznačeni time da hialuronska kiselina upotrijebljena za pripravu ACP i HBC derivata jest preferirano hialuronska kiselina u obliku natrijeve soli koja ima prosječnu molekulsku masu od 400 do 3x106 Da, preferirano od 3x105 Da do 3x106 Da, a najpreferiranije od 200 000 do 750 000 Da.
characterized in that a pair of slides (88, 90) are slidable on a stationary slide shaft (86) parallel to said carriage shaft on opposite sides of said carriage, disconnected from said carriage and freely slidable with respect to said carriage and said carriage shaft, and 
što su dva klizača (88, 90), koji se mogu pomicati po stacionarnoj šipki za vođenje (86) klizača koja je postavljena paralelno s navedenom šipkom za vođenje kliznog elementa, postavljeni na suprotnim stranama navedenog kliznog elementa, odvojeni od navedenog kliznog elementa, i mogu slobodno klizati u odnosu na navedeni klizni element i na navedenu šipku za vođenje, i
centrifuging to remove a supernatant, and washing the resulting precipitate once or twice with 95% ethanol, followed by resuspending in distilled water; 
centrifugiranja da se ukloni supernatant, te ispiranja dobivenog taloga jednom ili dva puta sa 95% etanolom, te zatim resuspendiranja u destiliranoj vodi;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
In one aspect, the invention provides a method of treating a patient with an autoimmune ocular inflammatory disease, comprising administering to the patient an IL-17 antagonist. 
PATENTNI ZAHTJEVI 1. 1IL-17 antagonist, naznačen time, da se koristi u liječenju pacijenta s autoimunom očnom upalnom bolesti (AOID).
A compound of the formula (I) 
2. Spoj formule (I) x
The compound according to [10] or a pharmacologically acceptable salt thereof, wherein in the formula (I), Ar1 is a group selected from the group consisting of B1), B6b), and B9c1): 
Spoj u skladu sa patentnim zahtjevom 10 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (1), Ar' je grupa odabrana iz grupe koja se sastoji od B1), B6b), i B9c1):
xiv) negative for tumor growth in Severely Compromised Immuno-Deficient (SCID) mice; 
negativna za tumorski rast kod SCID miševa;
Depending on the increase in the thickness of a stratum and the viscosity and amount of oil being produced, the number of ultrasonic radiators varies from 1 to more, changing towards an increase. 
Ovisno o povećanju debljine naslaga to viskoznosti i količine proizvedene nafte, broj ultrazvučnih radijatora varira od 1 na više, idući prema povećanju.
a biologically effective amount of the compound of Claim 1 or the composition of Claim 10; and a propellant. 
(a) biološki efikasnu količinu spoja iz Zahtjeva 1 ili smjesu iz Zahtjeva 10; i
In this synthesis is obtained a high yield without the need of purifying product 3 for later use. Then, the naphthyl derivative 3 is used as acylating agent. The compound 3 is selective for primary amino groups, such as linear or branched aliphatic diamines (ethylenediamine, propylenediamine, 1-methyl-1, 2-ethylenediamine, butylenediamine) and polyfunctional amines such as a-aminoacids; thioamines, aminoalcohols and aminocarboxylic acids (a-aminoisobutyric acid, 2-aminoethanethiol, ethanolamine, B-alanine, 6-aminohexanoic acid, etc.). 
Postupak za pripremu derivata naftalena strukture I, prema zahtjevima 1 i 2, koji u Ry nose neku kiselinsku ili amino terminalnu skupinu, naznačen reakcijom acilacijskog sredstva, N-hidroksisukcinamid estera 4-(1- naftalimino)-4-oksobutanoične kiseline prema zahtjevu 4, pri čemu spojevi imaju primarne amino skupine kao što su alifatski diamini, linearni ili razgranati, i polifunkcionalne amine kao što su a-amino kiseline, tioamini, aminoalkoholi i aminokarboksilne kiseline, u prisutnosti neke organske baze ili bez nje, u DMF-u ili 1,4-dioksanu kao otapalu.
The method of claim 22, wherein the long-lived plasma cells or memory B-cells are purified from the secondary lymph glands, bone marrow or spleen of the antigen-challenged, non-human transgenic mammal. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da antigenom izazvan, ne-humani transgeni sisavac je miš, a dugovječne plazma stanice ili memorijske B-stanice su pročišćene iz sekundarnih limfnih čvorova, koštane srži ili slezene miša.
The “film” thickness of the top coating after drying was about 8 
Debljina,,filma" gornjeg sloja nakon sušenja iznosila je oko 8 um.
Also provided is the use of (b) an M3 antagonist of the invention for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (a) a corticosteroid for the treatment of a said respiratory disease in a human or animal patient. 
Također je omogućena uporaba (a) B2-agonista za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s (b) M3 antagonistom sukladno predmetnom izumu za liječenje respiratornih bolesti koje odgovaraju na M3 antagonizam u bolesnih ljudi ili životinja.
The aqueous preparation according to claim 1, which is preserved relative to bacteria selected from the group consisting of Thermus sp., Propionibacterium sp., Rhodococcus sp., Panninobacter sp., Caulobacter sp., Brevundimonas sp., Asticcacaulis sp., Sphingomonas sp., Rhizobium sp., Ensifer sp., Bradyrhizobium sp., Tepidimonas sp., Tepidicella sp., Aquabacterium sp., Pelomonas sp., Alcaligenis sp., Achromobacter sp., Ralstonia sp., Limnobacter sp., Massilia sp., Hydrogenophaga sp., Acidovorax sp., Curvibacter sp., Delftia sp., Rhodoferax sp., Alishewanella sp., Stenotrophomonas sp., Dokdonella sp., Methylosinus sp., Hyphomicrobium sp., Methylosulfomonas sp., Methylobacteria sp., Pseudomonas sp., and mixtures thereof. 
te njihove mješavine, a još poželjnije sadrži bakterije odabrane iz skupine koja sadrži Pseudomonas putida, Pseudomonas mendocina, Pseudomonas fluorescens, Pseudomonas alcaligenes, Pseudomonas pseudoalcaligenes, Pseudomonas entomophila, Pseudomonas syringae, Methylobacterium extorquens, Methylobacterium radiotolerants, Methylobacterium dichloromethanicum, Methylobacterium organophilu, Hyphomicrobium zavarzini te njihove mješavine.
Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which 
Harl je izborno supstituiran s R6111 i/ili R6112 i monociklički je ili kondenzirani biciklički 5- do 10-eročlani nezasićeni heteroaromatski prsten, koji sadrži jedan do tri heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik i sumpor, gdje
Method and system for transmitting satellite signals and receiver thereof 
METODA I SISTEM ZA PRIJENOS SATELITSKIH SIGNALA | PRIJEMNIK ISTIH
mixing all of said coarse particles of a physiologically acceptable excipient; all of said salt of a fatty acid; a first portion of said micronized particles of a physiologically acceptable excipient; and all of said micronized particles of said long-acting B2-agonist, said anti-muscarinic drug, and, optionally, said inhaled corticosteroid in a vessel of a shaker mixer at a speed of rotation of 20 to 28 rpm for a time of 60 to 120 minutes, to obtain a first mixture; and 
miješanje svih rečenih grubih čestica fiziološki prihvatljivog ekscipijensa, sve rečene soli masne kiseline, prvog dijela rečenih mikroniziranih čestica fiziološki prihvatljivog ekscipijensa, svih rečenih mikroniziranih čestica rečenog dugodjelujućeg B2-agonista, rečenog antimuskarinskog lijeka, te, opcionalno, rečenog kortikosteroida za inhalaciju u posudi miješalice s potresivanjem pri brzini rotacije ne manjoj od 16 r.p.m. u vremenu ne manjem od 60 minuta, da se dobije prva smjesa; te
The reaction mixture was added to a saturated aqueous solution of ammonium chloride, extracted with a mixture of dichloromethane/methanol in the proportions 100/0 to 80/20, dried and evaporated. 
Reakcijska smjesa doda se u zasićenu vodenu otopinu amonijevog klorida, ekstrahira smjesom diklormetan/metanol, u odnosima od 100/0 do 80/20, osuši, te otpari.
Process according to any of claims 1 to 7, characterised in that the di and/or trivalent cation salt(s) of one or more C8 to C24 aliphatic carboxylic acid(s) are di and/or trivalent cation salt of one or more C10 to C18, and preferably are di and/or trivalent cation salt of one or more C12 to C18 aliphatic carboxylic acid(s). 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time da dvovalentna i/ili trovalentna sol kationa jedne ili više Ca do Cy alifatske karboksilne kiseline odnosno alifatskih karboksilnih kiselina su dvovalentna i/ili trovalentna sol kationa jedno ili više Cio do Cig alifatskih karboksilnih kiselina, a poželjno su dvovalentna i/ili trovalentna sol kationa jedne ili više Ci» do Cig alifatske karboksilne kiseline odnosno alifatskih karboksilnih kiselina.
as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof. 
kao i njihovi oblici racemata, tautomeri, enantiomeri, diastereomeri, epimeri i polimorfi i njihove smjese, te njihove farmaceutski prihvatljive soli.
and in that the treatment steps A1) to C) are incorporated in the treatment steps of a wastewater purification plant (100), which comprise at least: denitrification, oxidation, nitrification and secondary sedimentation. 
pri čemu su koraci obrade A1) do C) inkorporirani u korake obrade otpadne vode u postrojenju za pročišćavanje otpadne vode (100).
Injection is via the external surface of the urethra and toward the submucosal membrane. 
Injektira se preko vanjske površine mokraćne cijevi i prema submukoznoj membrani.
The ophthalmic aqueous solution according to any one of claims 1 to 4 in a container comprising minor amounts of polypropylene, polyethylene terephthalate, polyvinyl chloride, acrylic resins, polystyrene, polymethyl methacrylate or nylon 6. 
Oftalmološka vodena otopina prema bilo kojem od zahtjeva 1 do 4, gdje sredstvo za podešavanje pH je natrijev hidroksid i/ili klorovodonična kiselina.
The method according to claim 8, wherein the anti-solvent is acetone or ethyl acetate. 
Postupak sukladno zahtjevu 8, naznačen time što je anti-otapalo aceton 1li etil acetat.
The pharmaceutical composition of embodiment 48, wherein said sodium chloride is present is said formulation at a concentration of about 150 mM. 
Farmaceutski sastav prema zahtjevu 28, naznačen time da je navedeni natrijev klorid prisutan u navedenoj formulaciji u koncentraciji od oko 150 mM.
The thiazolidin-4-one derivative according to claim 5 or 6, wherein R14 represents an unsubstituted phenyl group. 
Derivati tiazolidin-4-ona prema zahtjevima 4 i 5, naznačeni time, da R'* predstavlja nesupstituiranu, ili mono- ili di-supstituiranu fenilnu skupinu.
A combination for use according to any one of claims 1 to 3, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, GSK-159797,KUL-1248,TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija prema zahtjevu 1 ili 2, naznačena time, da je B2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuterol, klenbuterol, dopeksamin, fenoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)-formoterol, reproterol, ritodrin, rimoterol, salbutamol, sibenadet, sulfonterol, terbutalin i tulobuterol, po izboru u obliku njihovih racemata, njihovih enantiomera, njihovih diastereomera i njihovih smjesa, te prema potrebi njihovih farmakološki kompatibilnih kiselinskih adicijskih soli.
B is the B-chain of insulin lispro (SEQ ID NO: 3); and wherein A and B are properly cross-linked and P is attached via an urethane covalent bond to the epsilon-amino group of the lysine at position 28 of B; 
B je B-lanac inzulina lispro i ima aminokiselinski slijed SEQ ID NO: 3; i P je PEG čija je molekulska težina u rasponu od otprilike 17,5 kDa do otprilike 40 kDa, te gdje su A i B odgovarajuće umreženi, a P je vezan preko uretanske kovalentne veze na e-amino skupinu u lizinu na položaju 28 u B.
Alternative raw materials, such as industrial byproducts, which are used as components of the raw meal mixture of the hydraulically reactive clinker according to the invention, are not disclosed in EP 1 171 398 B1. 
Postupak sukladno barem jednom od zahtjeva 1 do 3, naznačen time što materijali, koji opskrbljuju mineralizatore, poželjno fosfati, fluoridi, alkali, nitrati i/ili kloridi, dodaju se sirovoj smjesi.
The compound of Claim 1, which is characterized by an x-ray powder diffraction pattern (CuKa X=1.5418Å at a temperature of about 23°C) comprising four or more 2θ values selected from the group consisting of: 18.± 0.2,18.4± 0.2, 19.2± 0.2, 19.6± 0.2, 21.2± 0.2, 24.5± 0.2, 25.9± 0.2, and 28.0± 0.2. 
(IV). 2. Spoj prema patentnom zahtjevu 1, naznačen time, što je prikazan dijagramom rendgenske difrakcije praha (CuKo X = 1.5418 A na temperaturi od oko 23%C) koji sadrži četiri ili više 20 vrijednosti izabranih iz grupe koju čine: 18.0 3.
In another mode, the sealing material is an integral part of the outer face of the capsule. 
Kod nekog drugog postupka, materijal za brtvljenje je integralni dio vanjske plohe čahure.
The expression vector according to the preceding claim, wherein the serotype is 1, 2, 5, 7, 8 or 9. 
Genski konstrukt u skladu s patentnim zahtjevom 4, naznačen time što je serotip adenoasociranog vektora 1, 2, 5, 7, 8 ili 9.
In some embodiments, at least about 80% by weight of the N N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide is in an amorphous form. 
Kruta disperzija prema bilo kojem od zahtjeva 1 do 7, naznačena time da je N-[2,4-bis(1,1-dimetiletil)-5hidroksfenil|-1,4-dihidro-4-oksokinolin-3-karboksamid prisutan u količini od 10% masenih do 80% masenih.
Anaerobic digested biomass obtained by anaerobic digestion of water living organisms from the species Ciona intestinalis and Ciona savignyi. 
Anaerobno razgrađena biomasa dobivena anaerobnom digestijom vodenih živih organizama vrsta Ciona intestinalis i Ciona savigny.
The use of the thermoplastic film of any of claims 1 to 10 or 12, or the product of claim 11, for packaging, for silage applications or for manual packaging applications. 
13. Uporaba termoplastične folije 1z bilo kojeg od zahtjeva 1 do 101ili 12, ili proizvod iz zahtjeva 11, za pakiranje, za primjenu silaže 1li za ručno pakiranje.
The method of claim 8, wherein the anti-sticking agent is talc. 
Postupak prema patentnom zahtjevu $, gdje je sredstvo protiv sljepljivanja talk.
Where m′ is 1, 2 or 3, the reaction is suitably effected in the presence of a source of iodide such as sodium iodide or potassium iodide, and at a temperature in the range, for example, 10 to 150° C. (or the boiling point of the solvent), suitably in the range 20 to 90° C. For example, when m is 1, the reaction may be conducted using triethylamine as a suitable base, potassium iodide as a suitable iodide source and N, N -dimethylacetamide as a suitable solvent or diluent at a temperature of about 80° C. 
Kada je m' jednak I, 2 ili 3, reakcija se prikladno provodi u prisutnosti izvora jodida, poput natrij-jodida ili kalij-jodida i pri temperaturi u rasponu od, na primjer, 10 do 150 "C (ili pri točci vrenja otapala), poželjno u rasponu od 20-90 *C. Na primjer, kada je m jednak 1, reakcija se može provoditi sa trietilaminom kao prikladnom bazom, kalij-jodidom kao prikladnim izvorom jodida i N.N-dimetilacetamidom kao prikladnim otapalom ili razrjeđivačem pri temeperaturi od otprilike 80 *C.
The peptide for use according to claim 1, wherein it is used in an amount in a range from about 1 mg to about 20 mg. 
Peptid za uporabu prema zahtjevu 1, gdje se koristi u količini u rasponu od oko 1 mg do oko 20 mg.
Methanol (5 mL) was added and the mixture stirred at room temperature for 30 min and then evaporated in vacuo. 
Dodan je metanol (5 mL) i smjesa je miješana na sobnoj temperaturi 30 minuta I tada evaporirana in vacuo.
The balloon catheter according to claim 1, wherein the at least one water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate. 
Medicinski uređaj prema zahtjevu 1, naznačen time, da je PEG-sorbitan ester masnih kiselina odabran od sljedećih: Tween"* 20, Tween* 40, Tween" 60 ili Tween" 80.
metformin or/and a pharmaceutically acceptable salt thereof, particularly for oral administration. 
(c) metformin ilifi njegovu farmaceutski prihvatljivu sol, naročito za oralnu primjenu.
Sodium hydroxide is a preferred base. 
P je zaštitna skupina;
Anthemis tinctoria, yellow chamomile or golden marguerite. 
Anthemis tinctoria, žuta kamilica ili zlatna margareta 1.
in which R1 and R2 are as defined in claim 1 . 
(VI) pri čemu R! i Rž su kako je definirano u zahtjevu 1.
is an integer of 0 to 7, 
je cijeli broj od 0 do 7,
removing the hydroxyl protecting groups Rp1 and Rp2 simultaneously or consecutively to form the compound of formula I, with the proviso that in case that R1 is S-Rp3 the compound of formula VII is transformed in the presence of a molecular sieve into the disulfide derivative of formula IX before removing the hydroxyl protecting groups Rp1 and Rp2 wherein Rp4 is C1-C4alkyl, in particular methyl, or 3-nitro-2-pyridinyl, which compound is treated with a reducing agent, in particular trialkyl phosphine or triaryl phosphine, in a solvent, in particular aqueous acetone, DMF, dioxane or THF, to give a compound of formula X wherein Rp1 and Rp2 have the above meaning, which compound Is then reacted with a compound of formula Q-X-Lg, wherein Q and X are as defined In claim 1 and Lg is a leaving group or, when X represents a carbonyl or sulfonyl group, a vinyl group, to give a compound of formula VII wherein R1 is as defined in claim 1. 
m gdje Rpa je Ci-Cualkil, osobito metil, ili 3-nitro-2-piridinil, 20 gdje se navedeni spoj obrađuje reducensom, osobito trialkilfosfinom ili triarilfosfinom, u otapalu, osobito vodenoj otopini acetona, DMF-u, dioksanu ili THF-u, kako bi se dobilo spoj formule X HR P20090302 TI gdje Rp; i Rp, imaju gore navedeno značenje, te gdje navedeni spoj zatim reagira sa spojem formule Q-X-Lg, gdje Q i X su kao što je definirano u patentnom zahtjevu 1, a Lg je izlazna skupina, ili je, kada X predstavlja karbonilnu ili sulfonilnu skupinu, vinilna skupina, kako bi se dobilo spoj formule VII, gdje R1 je kao što je definirano u patentnom zahtjevu 1.
one or more gas-releasing compounds, and 
- < jedanili više spojeva koji oslobađaju plinove,
R10, R11 represent, independently from each other, a group selected from hydrogen, C1-C6-alkyl-, C3-C7-cycloalkyl-, heterocyclyl-, phenyl, benzyl or heteroaryl, 
R', R/ predstavljaju, međusobno neovisno, skupinu koja je odabrana od vodikovog atoma, fluorovog atoma, klorovog atoma, C;-C3-alkil-, C,-C2-alkoksi-, halo-C;-C3-alk1l-, C,-C3-fluoralkoksi-;
wherein the free covalent bond of L is joined to a protein carrier; wherein the protein carrier is as defined in claim 15; and wherein at least one of the Z groups and 80-99% of the Q groups are blocking groups as defined in claims 1 to 4, 1-20% of the Q groups are OAc and the remainder of the Q groups are OH. 
LjeO,NH, NE, S ili Se; gdje je slobodna kovalentna veza u L povezana s proteinskim nosačem; gdje je proteinski nosač u skladu s patentnim zahtjevom 15; te gdje su najmanje jedna od skupina Z i 60-99% skupina Q blokirajuće skupine u skladu s patentnim zahtjevima 1 do 4, 1-20% skupina Q su OAc, a ostatak skupina Q su OH.
The pharmaceutical composition of claim 5, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I') iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, gdje u formuli (I'), R1 je atom vodika, i R2 je atom vodika; hidroksi grupa; ravna ili razgranata C1-C6 alkil grupa; ravna ili razgranata C1-C5 alkoksi grupa; ili ravna ili razgranata C1-C3 tioalkil grupa.
The use of item 10, wherein said CD19 x CD3 bispecific single chain antibody is MT103. 
Glukokoritkoid za uporabu u skladu s patentnim zahtjevom 9, pri čemu je navedeno CD19 x CD3 bispecifično jednolančano protutijelo MT103.
The antibody or antigen binding fragment thereof or composition or pharmaceutical composition for use as defined in claim 18, wherein the cancer is selected from the group consisting of ovarian cancer, skin cancer, renal cancer, colorectal cancer, sarcoma, leukemia, brain cancer, thyroid cancer, breast cancer, prostate cancer, oesophageal cancer, bladder cancer, lung cancer and head and neck cancer and/or wherein the cancer is metastatic. 
Humanizirano protutijelo ili njegov fragment koji veže antigen ili pripravak ili farmaceutski pripravak za uporabu prema zahtjevu 13, naznačen time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak jajnika, rak kože, rak bubrega, kolorektalni rak, sarkom, leukemija, rak mozga, rak tiroidne žlijezde, rak dojke, rak prostate, rak jednjaka, rak mjehura, rak pluća i rak glave i vrata i/ili time, da je rak metastatski.
a second pump (4) installed in the fuel gas supply line to compress LNG from the LNG tank at a high pressure and supply the compressed LNG to the high-pressure gas injection engine; 
Sustav dobave pogonskog plina za plovilo prema zahtjevu 1 naznačen time da druga crpka komprimira LNG na približno 100 do 300 bar manometarskog tlaka 1 zatim dovodi komprimirani LNG u visokotlačni plinski injekcijski motor.
The method of claim 8, wherein the persisting population of genetically engineered T cells comprises at least one cell selected from the group consisting of a T cell that was administered to the human, a progeny of a T cell that was administered to the human, and a combination thereof. 
T stanica za upotrebu prema patentnom zahtjevu 7, naznačena time što perzistentna populacija genetski modificiranih T stanica sadrži najmanje jednu stanicu odabranu iz grupe koja se sastoji od T stanice koja je bila primjenjena kod čovjeka, potomstva T stanice koja je bila primjenjena kod čovjeka, i njihove kombinacije.
The computer implemented method of claim 1, further comprising initializing, by the computing device, the debugging process including creating a debugging process based upon, at least in part, the packed portable executable file. The computer implemented method of claim 1, wherein the original entry point includes a first instruction of executable code before the packed portable executable file was protected. 
Postupak kojeg provodi računalo u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje pokretanje, od strane računalnog uređaja, postupka uklanjanja pogrešaka, uključujući pokretanje postupka uklanjanja pogrešaka na osnovi, u najmanju ruku djelomično, pakirane prijenosne izvršne datoteke.